TABLE 2

Current Tumor and Peptide Receptor Candidates for PRRT

Administration route	Tumors	In vitro evidence	In vivo evidence
Administration route	Tumors	In vitro evidence			Diagnostic	PRRT (ref.)
Intravenous	Somatostatin receptor sst2-expressing tumors
	GEP NET*	+	+	+ (3,8,10,11)
	Paragangliomas*	+	+	+ (43)
	Pheochromocytomas*	+	+	+ (43)
	Small-cell lung cancer	+	+
	Medullary thyroid cancer	+	+	+ (43)
	Breast cancer	+	+
	Renal cell cancer	+	+
	Thyroid cancer	+	+	+
	Malignant lymphomas	+	+
	CCK2 receptor expressing tumors
	Medullary thyroid cancer*	+	+	+ (9)
	GIST*	+
	Small-cell lung cancer	+	+
	GEP NET	+	+
	Sex cord stromal ovarian tumor	+
Topical	sst2-expressing central nervous system tumors
	Medulloblastomas*	+	+	+
	Gliomas	+	+	+ (5,12)

↵* Most eligible for PRRT, on the basis of high incidence and density of receptors.